Alvogen’s Alymsys reimbursed...compete with Avastin similar
By Lee, Tak-Sun | translator Alice Kang
22.10.11 12:08:37
가나다라
0
Three-way race between Alvogen’s Alymsys, original Avastin, and Samsung Biologics’ Onbevzi
Sees mixed results in ovarian cancer... Samsung Biologics adds indication, Alvogen’s indication deleted
Celltrion also receives approval in September and aims at releasing its drug with reimbursement within the year
▲Samsung Bioepis’s Avastin biosimilar
Competition for biosimilars of the anticancer drug Avastin (bevacizumab) is intensifying in the domestic market. Alvogen’s ‘Alymsys’ is making a bid against Samsung Bioepis’s ‘Onbevzi,' which had been dominating the Avastin biosimilar market. With the entry of Alymsys, the original Avastin and its two biosimilars will be competing in the market.According to industry sources on the 11th, Alvogen Korea’s ‘Alymsys inj.’ will be included on the NHI reimbursement list starting this month.
The maximum reimbursement price for the 0.1g dose will be KRW 208,144 per vial, the same as Samsung Bioepis’s ‘Onbevzi inj.’ The price of the 0.4g dose was also set at KRW 677,471, the same as On
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)